|
Active substance |
Lurbinectedin |
|
Holder |
Pharma Mar, S.A. |
|
Status |
Running |
|
Indication |
The indication for the Compassionate Use Program (CUP) is: “Zepzelca (lurbinectedin), in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide”. |
|
Public documents |
|
|
Public documents |
01/07/2026 |
Zepzelca
Last updated on